Novavax is a late-stage biotechnology company dedicated to improving health globally through the discovery, development, and commercialization of innovative vaccines. Our proprietary recombinant technology platform combines the power and speed of genetic engineering to with the immunogenicity enhancing properties of our Matrix-M™ adjuvant to efficiently produce highly immunogenic nanoparticles with the potential to address some of the most urgent global health needs. Our product pipeline targets a variety of serious infectious diseases, from influenza to emerging infectious diseases. We are developing NVX-CoV2373, a vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™ is our quadrivalent influenza nanoparticle vaccine, which met all primary objectives in a pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Headquartered in Gaithersburg, Maryland, Novavax has additional facilities in Uppsala, Sweden and Bohumil, Czech Republic. Our employees worldwide are dedicated to developing novel vaccines to address infectious disease. Novavax is traded on NASDAQ under the symbol NVAX.

• Company Overview
• Established 1987
• Employees 501-1,000
• Email ******@novavax.com
• Websitehttp://www.novavax.com